Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Ali S, Sergeant R, O'Brien SG, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K.

Blood. 2012 Jul 19;120(3):697-8. doi: 10.1182/blood-2012-04-421016. No abstract available.

2.

Hematology: dasatinib regimens for patients with chronic myeloid leukemia.

Guilhot F, Roy L.

Nat Rev Clin Oncol. 2009 Dec;6(12):680-2. doi: 10.1038/nrclinonc.2009.160.

PMID:
19942922
3.
4.

Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.

De Melo VA, Milojkovic D, Khorashad JS, Marin D, Goldman JM, Apperley JF, Reid AG.

Blood. 2007 Oct 15;110(8):3086-7. No abstract available.

5.

Dasatinib for the treatment of chronic myeloid leukemia.

Fullmer A, Kantarjian H, Cortes J, Jabbour E.

Expert Rev Hematol. 2011 Jun;4(3):253-60. doi: 10.1586/ehm.11.20.

PMID:
21668392
6.

Dasatinib in chronic myelogenous leukemia.

Chu SC, Tang JL, Li CC.

N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4. No abstract available.

PMID:
16960978
8.

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.

Hochhaus A, Kantarjian H.

J Cancer Res Clin Oncol. 2013 Dec;139(12):1971-84. doi: 10.1007/s00432-013-1488-z. Epub 2013 Aug 13. Review.

9.

Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.

Keating GM, Lyseng-Williamson KA, McCormack PL, Keam SJ.

BioDrugs. 2013 Jun;27(3):275-9. doi: 10.1007/s40259-013-0024-7. Review.

PMID:
23549840
10.

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.

Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J.

Cancer. 2011 Nov 15;117(22):5085-93. doi: 10.1002/cncr.26147. Epub 2011 Apr 26.

11.

10 years of progress in chronic myelogenous leukemia.

Jabbour E, Mathisen MS, O'Brien S.

J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. No abstract available.

PMID:
22956803
12.

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.

Soverini S, Martinelli G, Colarossi S, Gnani A, Rondoni M, Castagnetti F, Paolini S, Rosti G, Baccarani M.

Lancet Oncol. 2007 Mar;8(3):273-4. No abstract available.

PMID:
17329198
13.

[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].

Gómez Casares MT, León LG.

Med Clin (Barc). 2013 Aug 4;141(3):111-3. doi: 10.1016/j.medcli.2012.12.011. Epub 2013 Feb 22. Spanish. No abstract available.

PMID:
23462544
14.

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.

Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M.

Haematologica. 2013 May;98(5):714-7. doi: 10.3324/haematol.2012.068890. Epub 2012 Oct 12.

15.

Management of Bcr-Abl-positive leukemias with dasatinib.

Hochhaus A.

Expert Rev Anticancer Ther. 2007 Nov;7(11):1529-36. Review.

PMID:
18020922
16.

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

Kreutzman A, Jaatinen T, Greco D, Vakkila E, Richter J, Ekblom M, Hjorth-Hansen H, Stenke L, Melo T, Paquette R, Seggewiss-Bernhardt R, Guerci-Bresler A, Talbot A, Cayuela JM, Mahon FX, Porkka K, Lipton J, Partanen J, Rousselot P, Mustjoki S.

Exp Hematol. 2012 Nov;40(11):906-913.e1. doi: 10.1016/j.exphem.2012.07.007. Epub 2012 Jul 25.

PMID:
22842045
17.

Dasatinib.

Shah NP.

Drugs Today (Barc). 2007 Jan;43(1):5-12.

PMID:
17315048
18.

Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.

Larsson N, Billström R, Lilljebjörn H, Lassen C, Richter J, Ekblom M, Fioretos T.

Cancer Genet Cytogenet. 2010 Jun;199(2):89-95. doi: 10.1016/j.cancergencyto.2010.02.005.

PMID:
20471511
19.

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.

Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G.

Leuk Res. 2011 Jul;35(7):e118-20. doi: 10.1016/j.leukres.2011.03.021. Epub 2011 Apr 12. No abstract available.

PMID:
21489624
20.

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.

Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC.

Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22.

PMID:
23433665

Supplemental Content

Support Center